<DOC>
	<DOCNO>NCT02164097</DOCNO>
	<brief_summary>This study pediatric patient refractory/recurrent solid tumor . They receive standard chemotherapy ( ICE ) investigate addition new drug , ODSH , help increase time platelet recovery ICE chemotherapy.The purpose study evaluate safety tolerability ODSH pediatric patient receive `` ICE '' chemotherapy .</brief_summary>
	<brief_title>ODSH + ICE Chemotherapy Pediatric Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Wilms Tumor</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Recurrent refractory solid tumor . This may include , limited , osteosarcoma , chondrosarcoma , Ewing 's sarcoma , Wilm 's Tumor , medulloblastoma , neuroblastoma , hepatoblastoma , rhabdomyosarcoma , retinoblastoma , primitive neuroectodermal tumor . Histologic proof malignancy must available time initial diagnosis . Age : 121 Patients must receive standard firstline chemotherapy appropriate standard first line therapy malignancy . Patients must radiologic histologic evidence recurrence Patients must fully recover toxic effect prior chemotherapy must ANC &gt; 1000/μL platelet count &gt; 100,000/μL Performance status &gt; 60 Lansky ( age 1 16 ) Karnofsky ( age &gt; 16 ) Adequate hepatic renal function ( AST , ALT , bilirubin creatinine &lt; 2.5 x upper normal limit ) . Parent guardian able provide inform consent sign approve consent form conform federal institutional guideline . Patients , investigator 's opinion , extensive bone marrow involvement tumor Presence significant active infection uncontrolled bleed Renal insufficiency , , opinion investigator , might adversely affect schedule dose therapy ICE chemotherapy . patient creatinine level ≥2 mg/dl eligible Preexisting liver disease , liver metastasis Use recreational drug within prior month Known history positive hepatitis B surface antigens HCV antibody Known history positive test HIV antibodies Patients receive form anticoagulant therapy Presence know bleed disorder coagulation abnormality Treatment investigational agent , participation another clinical trial within 28 day prior study entry Pregnant breastfeeding patient Patient childbearing potential use adequate contraception Hemorrhage risk require maintenance platelet count 50,000 high . Psychiatric neurologic condition could compromise patient safety compliance , interfere ability patient family give proper inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>ICE</keyword>
	<keyword>ODSH</keyword>
	<keyword>platelet recovery</keyword>
	<keyword>recurrent solid tumor</keyword>
</DOC>